VenetoMax

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

🚨 breaking news from #EHA2026 GILTERITINIB did NOT improve OS over MIDOSTAURIN IN 760-patient randomized phase 3 trial of their combinations with intensive chemo for newly diagnosed FLT3Mut #AMLsm trial
EHA Library; Jun 02 2026; 4214972
https://t.co/jSa9RgSKue

[VenetoMax @pk_mac]

@Fiatopichan พี้ค 555 นึกว่ารุตอนนอนห้องเด้น

[VenetoMax @pk_mac]

รอดอยู่

[ANGKRIZ [แองกริซ] @AngkrizAcademy]

⚠️ มาเพิ่มความท้าทาย ด้วยแบบทดสอบคำศัพท์ ระดับ C1 🔥

รอบนี้มาแบบ 4 ตัวเลือก
ถ้าพร้อมแล้ว ก็ไปกันต่ออออ 🎊
https://t.co/Kl79iaXrTs

#ANGKRIZ #C1
#dek69 #alevel69

[BENNEFRANK @BENNEFRANK13]

มุมมองความรัก 30+
- ไม่วิ่งตามอะไรใดๆ เหนื่อยง่ายวิ่งไม่ไปละ
- ให้เหนื่อยเพราะความรัก ขอเหนื่อยเพราะงานดีกว่า ยังได้ตัง
- ไม่ว่าจะเหนื่อยแค่ไหน ขอนอนก่อน
- รักตัวเอง ดูแลตัวเองให้มีความสุข เรื่องอื่น ช่างมัน 555
- ถ้าอะไรที่เหนื่อยใจ ไม่ใช่ ก็ตัดออกทันที

[VenetoMax @pk_mac]

@Fiatopichan หลังไมคได้ก่อออ

[VenetoMax @pk_mac]

@Fiatopichan บางที่คำนวณเอาปะคับ เลยต้องงด

[Henry C Fung| MM, lymphoma, leukemia & CART @HenrychihangFu1]

💣 AZA + VEN doesn’t fail—execution does.

Day 21 marrow decides everything.
Shorten VEN, not AZA.
Don’t wait for perfect counts.

Here’s how we induce AML in 2026 👇

Please let us know your approach.

#AML #HemeTwitter

Dr Fun + G

[Henry C Fung| MM, lymphoma, leukemia & CART @HenrychihangFu1]

Leukemia classification has evolved.

Morphology → risk → genetics.

Each step brought us closer to biology.

But genetics alone is not enough.

KMT2A-rearranged leukemia
NPM1-mutated AML

Different mutations.

Same biology:
HOXA9 / MEIS1 activation driven by the menin–KMT2A complex.

This is why both respond to menin inhibitors.

The next step?

👉 Biology-based classification

Menin-dependent leukemia

~6,000–8,000 cases/year in the U.S.
(~25–35% of AML + subset of ALL)

Different mutations. Same addiction.

Dr Fun + G

#AML #Hematology #PrecisionOncology #Hemetwitter

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

POEMS Syndrome: Clinical Manifestations, Pathophysiology, and Therapeutic Approaches @japacademy Aala Dweik ,Hadeel Dweik #mmsm @utswcancer

➡️https://t.co/5EWhHfD1Wp

[𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM @nihardesai89]

🎉 Out now in the British Journal of Haematology 🙌🏽

⤵️ PTCy to 35 mg/kg improves platelet engraftment and ⤵️ bloodstream infections peri-transplant WITHOUT ⤴️ acute GvHD after MUD transplant 💪🏽

Team @pmcancercentre 🙌🏽

@BrJHaem
https://t.co/wP6TIP6wDL

[Vincent Rajkumar @VincentRK]

Just out in @NEJM
Effective therapy of extra medullary relapsed myeloma with teclistamab plus talquetamab (Tec-Tal). RedirecTT-1 #ASH25
@myelomaMD @szusmani @mvmateos

80% response rate.
60% PFS at 12 months.
https://t.co/fqAPu4pMUc

[Andres Gomez @GomezDLeonMD]

Aza-Ven should be the standard in LMICs where 7+3 is way more toxic #ASH25 #Leusm

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

🚨 This is it people … you heard it first at #ASH25 🚨
ELN #MRD 205 guidelines are in press in @BloodPortfolio
Bad news: It’s more complicated than before… 🤯
Good news: there’s an app for it 😉
https://t.co/S0p6gDIQmk

[Uriel Suárez @UsuarezMD]

Some relevant abstracts on hematologic malignancies (12):
1. https://t.co/ncqco4E5nf

TAKEAWAYS:

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

This article reviews current approaches to salvage #alloHCT for primary graft failure, highlighting a promising one-day conditioning strategy and the urgent need for standardized regimens to improve outcomes. https://t.co/8GfBEp2gn6

[Dr Rishabh Jain @DrRishabhOnco]

💥 GLOFIT-POLA delivers CAR-T–like efficacy in R/R LBCL!
Phase Ib/II

🧪 Regimen
Obinutuzumab pre-dose ➕ Pola 1.8 mg/kg × 6 cycles ➕ Glofitamab 2.5→10→30 mg �� 12 cycles

👥 Population
129 pts | HGBCL 34% | Prior CAR-T 22% | Primary Refractory 62%

🎯 Results (IRC)
✅ ORR 78% | CR 60%
🕒 Median PFS 12.3 mo | OS 33.8 mo
💪 HGBCL CR 66% | Post-CAR-T CR 50%

⚠️ Safety
CRS 43% (Gr 1-2 = 42%) | Grade ≥3 AEs 59% | Fatal AEs 9%

🧩 Takeaway
Fixed-duration, off-the-shelf, chemo-light regimen - durable & manageable.
Next → #SKYGLO frontline trial.

#Lymphoma #DLBCL #Bispecifics #CAR-T #OncoTwitter @ASCO @esmo_open @OncoAlert

📖 Hutchings et al. J Clin Oncol 2025.
🔗 https://t.co/2gDIbuR77z

[Talha Badar @TalhaBadarMD]

AML-defining cytogenetic and molecular abnormalities (regardless of blast count)between the WHO 5th Edition (2022) and the International Consensus Classification (ICC 2022). #leusm #MedTwitter #hemonctrainees #when_on_service

[Dr Rishabh Jain @DrRishabhOnco]

🧬 Not all DLBCLs are created equal - POLA knows the difference.

📊 Real-world (n = 740, 2015–24)
Polatuzumab used in
🔹Frontline (305)
🔹R/R (435)
COO classified by Hans IHC algorithm

🔥 R/R LBCL:
•ORR 59.7% vs 36.3% ➜ OR 2.6 (p<0.0001)
•CR 35.7% vs 17.7% ➜ OR 2.6 (p<0.0001)
•PFS benefit → HR 0.64 (p = 0.0006)

💊 Frontline (Pola-R-CHP):
No subtype gap → Pola neutralizes COO risk

💡 Takeaway:
Hans IHC still rules 🧪
🔹 Non-GCB = POLA favorite in R/R
🔹 Frontline Pola-R-CHP = great equalizer

📖 Scheffer-Cliff et al., Clin Cancer Res 2025
DOI: https://t.co/ebpJRjuCbI

#DLBCL #Lymphoma #HemOnc #OncoTwitter #ESMOOpen
@OncoAlert @esmo_open @ASCO

[Dr. Chokri Ben Lamine @abouabdrahman0]

🔥 KMT2A-rearranged & NPM1-mutated AML – Why Menin Inhibitors Work 🔬

🧬 KMT2A (MLL) biology
•Chromatin modifier controlling HOX gene expression
•HOX overexpression = leukemogenesis (blocks differentiation)

🧩 Menin = key cofactor
•Acts as a scaffold protein that links KMT2A → HOX genes
•Required for transcriptional activation in KMT2Ar and NPM1-mut AML

💣 Pathogenic mechanism
•KMT2A rearranged AML → ↑ HOXA/MEIS1 → leukemia
•NPM1-mut AML uses menin–KMT2A pathway despite no rearrangement → same HOX overdrive

🛑 Solution: MENIN INHIBITION
•Menin inhibitors (e.g. Revumenib) block KMT2A–menin interaction
•↓ HOXA/MEIS1 → restores myeloid differentiation ✅
•Leads to deep remissions + MRD negativity in trials

✨ Why it matters
•Targets genetic core driver in KMT2Ar & NPM1-mut AML
•Works in relapsed/refractory and post-transplant relapse
•Differentiation-like activity similar to ATRA in APL (conceptually)

#AML #KMT2A #NPM1 #Menin #Revumenib #TargetedTherapy #Leukemia #Hematology #SOHOKSA #SOHO

[Dr. Chokri Ben Lamine @abouabdrahman0]

🧵 NEJM 2025 MGUS Review 🩸🔬

1️⃣ MGUS = Premalignant plasma-cell disorder
🔹 Seen in ~5% of adults >50y 👴👵
🔹 Risk of progression → myeloma, WM, or plasmacytoma ≈ 1%/yr
���� Can cause organ damage → MGCS (kidney 🩺, nerves 🧠, skin 🟤, thrombotic 🩸)

2️⃣ Pathogenesis 🔎
🔹 First hit: trisomies / IGH translocations
🔹 Progression: ↑ clone size + secondary hits (APOBEC, MYC, RAS/MAPK) + immune escape
🔹 Often silent for years before MM diagnosis

3️⃣ Diagnosis 🧪
🔹 M-protein <3 g/dL + <10% BM plasma cells + no CRAB 🚫
🔹 Use SPEP/IFE or mass spectrometry 💻
🔹 Always check FLC ratio 🔥
🔹 Imaging only if higher risk or suspicious 🩻

4️⃣ Risk stratification 📊
🔹 Factors: M-protein ≥1.5 g/dL 📈, IgA/IgM type, abnormal FLC ratio ⚠️
🔹 20-yr risk ↑ to 58% if all 3 factors present vs 5% if none
🔹 Use iSTOPMM calculator to decide on baseline BM biopsy

5️⃣ Management 💊
🔹 No routine therapy 🚫
🔹 Monitor at 6 mo → yearly if stable ⏳
🔹 Aim: detect progression before organ damage
🔹 Treat MGCS (e.g., AL amyloidosis, MGRS, POEMS) with clone-directed Rx 🩹

6️⃣ Key complications ⚠️
🔹 MGRS → GN, C3 disease 🩸 → needs renal biopsy
🔹 MGNS → sensory neuropathy 🤲
🔹 Bone loss & ↑ thrombotic risk 🦴🩸

7️⃣ Prognosis 📈
🔹 Lifetime risk of progression ≈11% at 25 yrs
🔹 Risk persists—doesn’t fade over decades
🔹 Emerging tools: genomics 🧬, single-cell RNAseq 🧫, immune/micro-env profiling 🌐

🙏 Credit to Dr. Mohammed Al-Shahrani for sharing this landmark review with the hematology community 🌟 — empowering earlier recognition, smarter follow-up & precision care for MGUS patients.

#MGUS #NEJM2025 #MGRS #MGNS #Hematology #ClinicalPearls